Announcements Trials
Browse Landscape

Phase

Phase 2 33Phase 1/2 6Phase NA 4Phase 1 2Phase EARLY_PHASE1 1Phase 3 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Rhabdoid Tumor 2Medulloblastoma 2Ependymoma 2Brain Neoplasms 2Recurrence 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Neurotoxicity Syndromes 1Muscle Invasive Bladder Urothelial Carcinoma 1Lymphoma, T-Cell, Peripheral 1Lymphoma, Mantle-Cell 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma 1Leukemia, Large Granular Lymphocytic 1Central Nervous System Neoplasms 1Burkitt Lymphoma 1

Interventions

Cyclophosphamide 4Rituximab 3ibrutinib 2Peripheral Blood Stem Cell Transplantation 2venetoclax 1pegylated granulocyte colony-stimulating factor, human 1pegfilgrastim 1ibritumomab tiuxetan 1fludarabine phosphate 1fludarabine 1brexucabtagene autoleucel 1acalabrutinib 1Vincristine 1Surveys and Questionnaires 1Sugars 1Standard of Care 1Sirolimus 1Ribavirin 1Precision Medicine 1Practice Guidelines as Topic 1Pneumococcal Vaccines 1Pemetrexed 1NVP-BKM120 1Methotrexate 1Loratadine 1Immunohistochemistry 1Immunoenzyme Techniques 1Granulocyte Colony-Stimulating Factor 1Filgrastim 1Etoposide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase EARLY_PHASE1 × Lymphoma, Mantle-Cell × Methotrexate × Clear all
NCT01184885 2025-05-04

A Pilot Study to Determine the Safety and Tolerability of Sirolimus Given With Hyper-CVAD Chemotherapy

Thomas Jefferson University

Phase EARLY_PHASE1 Completed
7 enrolled 8 charts
LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Recurrence, Lymphoma, Mantle-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡